Truist analyst David MacDonald reiterated a Buy rating and $375 price target on Cigna (CI) after the company said it would invest $3.5B in Shield Health Solutions. The firm thinks Cigna’s broad and differentiated capabilities within the high-growth specialty market provides strong positioning and opportunity to further capture additional healthcare spend dover time, and thinks the investment likely aids execution on Cigna’s 8%-11% long-term average annual adjusted income growth target within the Specialty portfolio. The firm also views the investment as further building upon Evernorth’s robust specialty pharmacy capabilities at Accredo following previous acquisitions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna files automatic mixed securities shelf
- Cigna’s Evernorth Health invests $3.5B in Shields Health Solutions
- Cigna Reaffirms 2025 Earnings Projection Amid Industry Challenges
- ACA Rule Pause Offers Relief to UnitedHealth (UNH) and Peers Facing Rising Costs
- Gilead Sciences Stock (GILD) Turns Negative As CVS Says No To HIV Prevention Drug